Cannabis Effects on Brain Morphology in Aging
Maneno muhimu
Kikemikali
Tarehe
| Imethibitishwa Mwisho: | 03/31/2019 |
| Iliyowasilishwa Kwanza: | 06/02/2013 |
| Uandikishaji uliokadiriwa Uliwasilishwa: | 06/05/2013 |
| Iliyotumwa Kwanza: | 06/10/2013 |
| Sasisho la Mwisho Liliwasilishwa: | 04/17/2019 |
| Sasisho la Mwisho Lilichapishwa: | 04/21/2019 |
| Tarehe halisi ya kuanza kwa masomo: | 12/31/2012 |
| Tarehe ya Kukamilisha Msingi iliyokadiriwa: | 11/30/2018 |
| Tarehe ya Kukamilisha Utafiti: | 11/30/2019 |
Hali au ugonjwa
Awamu
Vikundi vya Arm
| Mkono | Uingiliaji / matibabu |
|---|---|
| Cannabis users ⋄Heavy Marijuana Users : 60-80 years old; Marijuana use initiated in adolescence with marijuana use of no more than 1-2 x/month after 30 years of age; Used marijuana more than 20 times/month for at least 1 year during this period. Cigarette smoking (tobacco) and alcohol will be allowed in both groups, which will be matched on number of smokers and nicotine dependence, measured according to the Fagerstrőm Test for Nicotine Dependence. Light alcohol use will also be allowed in and matched across both groups (< 14 drinks/week for men; < 7 drinks/week for women; may not meet DSM-IV criteria for alcohol dependence). | |
| Clean or Non-Users ⋄No marijuana use, may smoke cigarettes, fewer than 7 drinks/week (women) or 14 drinks/week (men). 60-80 years old. |
Vigezo vya Kustahiki
| Zama zinazostahiki Kujifunza | 60 Years Kwa 60 Years |
| Jinsia Inastahiki Kujifunza | All |
| Njia ya sampuli | Non-Probability Sample |
| Hupokea Wajitolea wa Afya | Ndio |
| Vigezo | Inclusion Criteria - Subjects will be 60 heavy users or non-users between 60-80 years of age - Participants who used marijuana during adolescence. Current marijuana usage not allowed and subjects must complete urine screening at the time of inclusion. Exclusion Criteria - Major psychiatric disorders, such bipolar disorder or schizophrenia as revealed by the Structured Clinical Interview for DSM-IV Disorders (100) and exclude for confounding psychiatric conditions - Evidence of untreated depression as determined by a HAM-D Score of >12 (17-item version) or untreated anxiety by a score of > 8 on the Hamilton Anxiety Scale - Evidence of neurologic or other physical illness that could produce cognitive deterioration. - Volunteers with a history of TIAs, carotid bruits, or lacunae on MRI scan will be excluded - History of myocardial infarction within the previous year or unstable cardiac disease - Uncontrolled hypertension (systolic BP > 170 or diastolic BP > 100) - History of significant liver disease - Clinically significant pulmonary disease, diabetes, or cancer - Because medications can affect cognitive functioning, subjects needing medicines that could influence psychometric test results will be excluded. These include: centrally active beta-blockers, narcotics, clonidine, anti-Parkinsonian medications, systemic corticosteroids, benzodiazepines, medications with significant cholinergic or anticholinergic effects, anticonvulsants, or warfarin, and any affecting the serotonin system, which may affect neuropsychological test results. - Current diagnosis or history of alcoholism or dependence on any illicit drugs other than marijuana. - Use of any investigational drugs within the previous month or longer, depending on drug half-life. - Contraindication for MRI scan (e.g. metal in body, claustrophobia). |
Matokeo
Hatua za Matokeo ya Msingi
1. Magnetic resonance imaging of hippocampal size [Participants will complete an MRI scan which will take approximately 1 hour]
2. Diffusion tensor imaging (DTI) to investigate white matter structure [Participants will complete an MRI scan with DTI sequence which will take approximately 1 hour]
3. Cognitive performance in a range of neuropsychological tests [Neuropsychological testing will take approximately 3 hours]
